<p>Canaccord Genuity 分析師 Caitlin Cronin 昨天對 TELA Bio 維持了買入評級，並設定了 4.00 美元的目標價。</p>
<h3>認識您的 ETF AI 分析師</h3>
<ul>
<li>瞭解 TipRanks 的 <em>ETF</em> AI 分析師如何幫助您做出更明智的投資決策</li>
<li>探索 TipRanks 用户喜愛的 ETF，並查看 <strong><em>ETF</em> AI 分析師</strong> 對您關注的 ETF 的見解。</li>
</ul>
<p>Caitlin Cronin 給予買入評級是基於反映 TELA Bio 戰略舉措和財務調整的多種因素。儘管公司在第三季度面臨挑戰，未能達到收入預期，並下調了全年指引，但 TELA Bio 對其商業戰略仍充滿信心。最近從 Abiomed 招募的經驗豐富的領導者預計將增強公司的銷售團隊，這對未來的增長至關重要。</p>
<p>此外，TELA Bio 通過 1300 萬美元的股權融資和增加債務能力，採取了增強財務靈活性的措施，這將支持其商業擴展努力。公司也在按計劃擴大銷售團隊，這預計將改善銷售業績。儘管面臨短期挑戰，但管理層在醫療科技領域的經驗以及 TELA 產品的質量為長期增長提供了堅實基礎。這些因素，加上更為保守的增長前景，支撐了 Cronin 對 TELA Bio 的買入評級。</p>
<p>在 11 月 14 日發佈的另一份報告中，Citizens JMP 也對該股票維持了買入評級，目標價為 5.00 美元。</p>

TELA

<p>Canaccord Genuity 分析師 Caitlin Cronin 對 TELA Bio 維持了買入評級，目標價為 4.00 美元，理由是其戰略舉措和財務調整。儘管未能達到第三季度的收入預期並下調了全年指引，TELA Bio 對其商業戰略仍充滿信心。該公司已聘請經驗豐富的領導者，籌集了 1300 萬美元的股權，並增加了債務能力以支持增長。Citizens JMP 也維持了買入評級，目標價為 5.00 美元</p>

<p>Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on TELA Bio yesterday and set a price target of $4.00.</p>
<div class="lb-trans"><p>Canaccord Genuity 分析師 Caitlin Cronin 昨天對 TELA Bio 維持了買入評級，並設定了 4.00 美元的目標價。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>認識您的 ETF AI 分析師</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>瞭解 TipRanks 的 <em>ETF</em> AI 分析師如何幫助您做出更明智的投資決策</li>
<li>探索 TipRanks 用户喜愛的 ETF，並查看 <strong><em>ETF</em> AI 分析師</strong> 對您關注的 ETF 的見解。</li>
</ul>
</div><p>Caitlin Cronin has given her Buy rating due to a combination of factors that reflect TELA Bio’s strategic initiatives and financial adjustments. Despite a challenging third quarter where the company missed revenue expectations and adjusted its full-year guidance downward, TELA Bio remains confident in its commercial strategy. The recent hiring of experienced leaders from Abiomed is expected to strengthen the company’s sales force, which is crucial for future growth.</p>
<div class="lb-trans"><p>Caitlin Cronin 給予買入評級是基於反映 TELA Bio 戰略舉措和財務調整的多種因素。儘管公司在第三季度面臨挑戰，未能達到收入預期，並下調了全年指引，但 TELA Bio 對其商業戰略仍充滿信心。最近從 Abiomed 招募的經驗豐富的領導者預計將增強公司的銷售團隊，這對未來的增長至關重要。</p>
</div><p>Additionally, TELA Bio has taken steps to enhance its financial flexibility through a $13 million equity raise and increased debt capacity, which will support its commercial expansion efforts. The company is also on track to meet its target of expanding its sales team, which is expected to improve sales performance. While there are short-term challenges, the management’s experience in the MedTech sector and the quality of TELA’s products provide a solid foundation for long-term growth. These factors, combined with a more conservative growth outlook, underpin Cronin’s Buy rating for TELA Bio.</p>
<div class="lb-trans"><p>此外，TELA Bio 通過 1300 萬美元的股權融資和增加債務能力，採取了增強財務靈活性的措施，這將支持其商業擴展努力。公司也在按計劃擴大銷售團隊，這預計將改善銷售業績。儘管面臨短期挑戰，但管理層在醫療科技領域的經驗以及 TELA 產品的質量為長期增長提供了堅實基礎。這些因素，加上更為保守的增長前景，支撐了 Cronin 對 TELA Bio 的買入評級。</p>
</div><p>In another report released on November 14, Citizens JMP also maintained a Buy rating on the stock with a $5.00 price target.</p>
<div class="lb-trans"><p>在 11 月 14 日發佈的另一份報告中，Citizens JMP 也對該股票維持了買入評級，目標價為 5.00 美元。</p>
</div>

儘管存在短期挑戰，戰略舉措和財務調整仍然支撐了對 Tela Bio 的買入評級